clinical dataHansa data supports full approval plan for IdefirixSwedish rare immunology specialist Hansa Biopharma AB has reported positive topline results from a European post-authorisation efficacy study of Idefirix, strengthening its case to convert the kidney … more ➔
artificial intelligenceEx-Palantir execs raise $12M to develop AI operating system at PercepticPerceptic has raised a $12 million (€10.3 million) seed round to advance an AI operating system used by companies including CSL. more ➔
oncologyAdcendo inks MSD supply deal to run ADC-Keytruda combination studyAdcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor. more ➔
CDC/Janice Haney CarrEli LillyThree in One Go: LimmaTech, Curevo, Vaccine CompanyShopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac … more ➔
obesityEU backs Novo Nordisk’s oral Wegovy for weight managementNovo Nordisk has moved a step closer to bringing an oral version of Wegovy to the European obesity market, after the Committee for Medicinal Products for Human Use (CHMP) recommended approval of once-daily … more ➔
clinical dataOSE’s Tedopi-Keytruda combo clears Phase II ovarian cancer hurdleFrench biotech OSE Immunotherapeutics has reported positive topline Phase II data for its cancer vaccine Tedopi in recurrent ovarian cancer, but the clinical signal is most clearly seen in combination … more ➔
lung cancerDays after J&J update, Nanobiotix pauses trading amid €75M stock offeringNanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect. more ➔
Clinical trialsInfex reports Phase IIa win for anti-Pseudomonas antibodyA new monoclonal antibody approach could add an infection-directed option to the changing treatment landscape for non-cystic fibrosis bronchiectasis. more ➔
biotech licensing dealsSERB to pay Hansa €110M upfront for EU rights to kidney transplant drugSERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug. more ➔
obesityHarbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity betHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform. more ➔
CDC/Janice Haney Carr
